Skip to main content
OpenTrials

Clinical trial condition

Recurrent Uterine Corpus Carcinoma

Explore clinical trials studying Recurrent Uterine Corpus Carcinoma. Study availability and eligibility vary by location and protocol.

30 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Uterine Corpus Carcinoma trial results

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

NCT02684227

Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, +6 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • The Woman's Hospital of Texas Houston, Texas, United States
  • MD Anderson in Katy Houston, Texas, United States
  • MD Anderson League City Nassau Bay, Texas, United States
View Trial Details
Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

NCT01307631

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +2 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Massachusetts General Hospital Charlestown, Massachusetts, United States
View Trial Details
Completed

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

NCT00063999

Conditions
Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, +3 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
View all 650 locations
View Trial Details
Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT00478426

Conditions
Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, +5 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 29 locations
View Trial Details
Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01132820

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +2 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Palo Alto Medical Foundation-Gynecologic Oncology Mountain View, California, United States
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
View all 87 locations
View Trial Details

Related conditions